50 results about "D-alpha Tocopherol" patented technology

The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.

The invention discloses paclitaxel nano micelle and an application thereof. The paclitaxel nano micelle is prepared from the following components shown in the following (1), (2) or (3): (1) a carrier and paclitaxel, wherein the carrier is a mixture of polyethylene glycol-distearoyl phosphatidyl ethanolamine (PEG-DSPE), D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) and dequalinium chloride; (2) a carrier and the paclitaxel, wherein the carrier is a mixture of the PEG-DSPE and the TPGS; and (3) a carrier and the paclitaxel, wherein the carrier is the PEG-DSPE. After the functionalized paclitaxel nano micelle disclosed by the invention is orally taken, the paclitaxel can penetrate through a barrier of gastrointestinal tract, thus the multi-drug resistance (MDR) of drug-resistant breast cancer is overcome. The oral formulation of the functionalized paclitaxel nano micelle disclosed by the invention can avoid the anaphylactic response, can be applied to numerous cancer patients and is also suitable for MDR tumors at the same time, thereby having great advantage compared with the traditional intravenous injection formulation.

The invention relates to a method for separating single tocopherol from mixed tocopherol, which takes the mixed tocopherol with a content of 50 percent to 100 percent as a raw material and adopts a four-area simulated moving bed chromatography system to separate a d-alpha-tocopherol, a d-beta-tocopherol, a d-gamma-tocopherol and a d-delta tocopherol with the purity and yield all more than 98 percent. As the simulated moving bed chromatography separation is a continuous process, the method has the advantages of high degree of production automation, simple technique, high production efficiency, continuous production and stable product quality. As an adsorbent and a solvent have low consumption, the whole separating device does not relate to chemical reactions.

The invention discloses a method for preparing high-purity natural vitamin E monomers by separating mixed tocopherol. The method comprises the following steps of: fully dissolving the mixed tocopherol in a mobile phase solvent I so as to obtain a loading solution; adding the loading solution into a reversed-phase chromatographic column; adding a mobile phase solvent II into the chromatographic column; and performing step-by-step collection to obtain effluent I of which the purity of d-alpha-tocopherol is more than or equal to 90 percent, effluent II of which the purity of d-gamma-tocopherol is more than or equal to 90 percent and effluent III of which the purity of d-delta-tocopherol is more than or equal to 85 percent. By the method, the one-time column loading and separation of raw materials can be realized under normal pressure so as to obtain three natural vitamin E monomers. A filler in the chromatographic column can be regenerated, the used solvents can be recovered, the cost is reduced, the method is convenient to operate, and the purity is high.

The invention discloses a method for separating D-alpha-tocopherol from mixed tocopherol, which comprises the following steps: an ionic liquid or a binary mixed solvent consisting of the ionic liquid and a polar solvent are taken as an extracting agent, and a fractional extraction method is adopted to efficiently separate the D-alpha-tocopherol from the mixed tocopherol containing the D-alpha-tocopherol, D-beta-tocopherol, D-gamma-tocopherol and D-delta-tocopherol. The method has the advantages of high separation efficiency, less solvent consumption, low production cost, safety, environmental protection, easy for industrialized production and so on.

An organic skin moisturizer comprised of Sea Buckthorn seed oil, Camellia seed oil, Argan seed oil, Pomegranate seed oil, Rosemary essential oil, d-alpha tocopherol, Tea Tree oil, Helichrysum oil, vitamin A palmitate. A lighter organic skin moisturizer comprised of Sea Buckthorn seed oil, Camellia seed oil, Argan seed oil, Pomegranate seed oil, Meadowfoam seed oil, Jojoba oil, d-alpha tocopherol, and Rosemary essential oil. And a damaged skin moisturizer, comprised of Sea Buckthorn seed oil, Tamanu oil, Meadowfoam seed oil, d-alpha tocopherol, Tea tree oil, and Vetiver oil.

The invention provides a nano-micelle drug carrier based on a vitamin E derivative, a nano-micelle drug composition as well as a preparation method and application of the nano-micelle drug composition. The nano-micelle drug carrier based on the vitamin E derivative is a nano-micelle formed by D-alpha-tocopherol polyethylene glycol 1000 succinate, D-alpha-tocopherol polyethylene glycol 2000 succinate and alpha-tocopherol succinate; and the carrier entraps a hydrophobic anti-tumor drug to obtain the nano-micelle drug composition. The D-alpha-tocopherol polyethylene glycol 1000 succinate, D-alpha-tocopherol polyethylene glycol 2000 succinate and alpha-tocopherol succinate are matched with one another and cooperate, so that the formed nano-micelle is good in stability, is small and uniform in grain size, improves drug encapsulation efficiency, has relatively good P-glycoprotein inhibiting ability, has good anti-tumor effect, is small in toxicity to normal cells and has good biocompatibility. The preparation method is simple and is wide in application prospect.

The invention belongs to the field of medicinal preparations, relates to a pH-sensitive polymeric micelle composition resisting tumor drug resistance, and especially relates to a pH-sensitive polymeric micelle composition resisting tumor drug resistance and encapsulating a poorly-soluble anti-tumor medicine. The pH-sensitive polymeric micelle composition resisting tumor drug resistance is constructed by employing two kinds of biologically-compactable pH-sensitive amphiphilic block polymer and an amphiphilic polymer D-alpha-tocopherol polyethyleneglycol succinate (TPGS) as a P-gp inhibitor in a certain ratio, and encapsulates a poorly-soluble anti-tumor medicine. Experiments prove that the polymeric micelle composition has pH-dependent release characteristic, is accumulated in tumor tissue in a high concentration, has specifically targeting inhibiting effect on growth of tumor cells generating drug resistance because of over expression of P-glycoprotein, and provides a novel carrier and preparation strategy for poorly-soluble anti-tumor medicines and reversing of drug resistance of tumor cells.

An organic skin moisturizer, which extends and improves the skin cells life cycle, comprised of Sea Buckthorn seed oil, Camellia seed oil, Argan seed oil, Pomegranate seed oil, Meadowfoam seed oil, d-alpha tocopherol, Lecithin oil, Rosemary essential oil, Tea Tree oil, Helichrysum oil, and Coffee Arabica oil. The oils are blended together resulting in a compound that is easily applied to the skin for superior results to keep the skin cells healthier longer. This compound was created to address the Hayflick limit, which is that all skin cells can only divide a specific number of times before the skin cell dies.

The invention discloses a method for preparing low-benzopyrene high-purity d-alpha tocopherol acetate. The method comprises the following steps of: mixing d-alpha tocopherol, an inert organic solvent and a catalyst in a certain ratio, controlling the temperature, performing esterification reaction on the mixture and acetic anhydride, mixing obtained crude d-alpha tocopherol acetate and a polar solvent, loading to a column, adsorbing by using resin so as to remove impurities, mixing the obtained product and the inert organic solvent, adding a removal agent in a certain ratio, circulating at the constant temperature of 60 DEG C for 2 hours in an external circulation mode, filtering, concentrating, desolventizing, and performing short-path molecular distillation refinement under high vacuum conditions to obtain the low-benzopyrene high-purity d-alpha tocopherol acetate. The content of the obtained product is high, and the content of the d-alpha tocopherol acetate is more than or equal to 98 percent; the specific rotation is more than or equal to +24 degrees; the concentration of heavy metals (based on Pb) is less than or equal to 10ppm; and the concentration of benzopyrene is less than or equal to 2ppb. The quality of products meets the standards established by developed countries in Europe and America.

The invention discloses D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS)-b-(polylactide (PLA)-ran-polyglycolide (PGA)) copolymer and a preparation method and application thereof. Structural formulas of the copolymer are shown as a formula I and/or a formula II, wherein n is 20 to 140, A+B+... is 2 to 690, and a+b+... is 2 to 840. The preparation method comprises the following steps of: putting 2 to 95 mass percent of lactide monomers, 2 to 95 mass percent of glycolide monomers and 3 to 40 mass percent of D-alpha-tocopherol polyethylene glycol 1000 succinate serving as raw materials into a reactor; adding a catalyst which accounts for 0.1 to 1 percent based on the total mass of the raw materials; and reacting in the absence of oxygen at the temperature of between 140 and 160 DEG C for 12 to 20 hours to obtain the TPGS-b-(PLA-ran-PGA) copolymer. The TPGS-b-(PLA-ran-PGA) copolymer prepared by the invention has high biocompatibility and biodegradability, and is applied to the fields of medicinal preparations and tissue engineering, particularly the field of medicinal preparations for resisting and treating tumor.

A clear aqueous formulation for topical application in the oral cavity of humans to treat leukoplakia contains water, beta-carotene, a water miscible polyol, an unsaturated fatty acid ester, and a surfactant, preferably polyethoxylated castor oil or POE(20) sorbitan monooleate The formulation preferably also contains a pharmaceutically acceptable anti-oxidant, preferably d-alpha-tocopherol (vitamin E), and is in the form of an oral rinse or as a gel well suited for spreading on gums or other parts of the oral cavity. The formulation is applied in a gel form on a substantially regular daily basis to areas in the oral cavity where leukoplakia lesions are present. Persistent application of the gel results in substantial diminution or total elimination of the leukoplakia lesions.

The invention discloses a kit for bisulfite conversion of free DNA. The kit comprises a bisulfite solution, a protective solution, washing liquor A, a magnetic bead suspension, washing liquor B, washing liquor C and eluate, wherein the protective solution is prepared from the following ingredients: 80% to 85% of tetrahydrofuran furfuryl alcohol, 10% to 15% of D-alpha tocopherol cetomacrogol 1000 succinate, 0.2% to 0.3% of tetrahydroglycosyl acetate, 0.05% to 0.1% of ethoxychrysoidine and the balance of water. The invention further provides a method for bisulfite conversion and DNA purificationof the free DNA by using the kit. According to the kit, a sulfite conversion method is subjected to great technological improvement, so that ctDNA conversion can be completed rapidly (40 to 60 minutes) under mild conditions (70 DEG C to 80 DEG C), pH of a system can be stabilized, ctDNA degradation is prevented, high-conversion-ratio, high-quality and high-purity free DNA can be rapidly obtained,and full automated operation of methylation researches is facilitated.

The invention discloses an ivermectin controlled-release capsule and a preparation method and application thereof. The ivermectin controlled-release capsule comprises, by mass, 0.1-1% of ivermectin raw material, 20-60% of water-soluble carrier and 30-70% of enteric-soluble wrapping material, the water-soluble carrier is one or multiple of hydroxypropyl-beta-cyclodextrin, methyl-beta-cyclodextrin,HPMC, PVP, PEG, poloxamer 188, mannitol, D-alpha-tocopherol PEG 1000 succinate, cholate/phospholipid mixed micelle, polyethylenediamine dendritic polymer, phospholipid or cholesterol, and the enteric-soluble wrapping material is one or multiple of hydroxypropyl methyl cellulose phthalic acid, acrylic resin II, acrylic III, cellulose acetate phthalate, polyethylene diacetate phthalate or hydroxypropyl methyl cellulose acetate succinate. The ivermectin controlled-release capsule has the advantage of outstanding acid resistance, enables drug to reach intestinal tracts to be disintegrated and released, remarkably improves bioavailability and has remarkable treatment effect.

The invention relates to the field of skin care products, in particular to a skin care product containing folium crataegi extract and a preparation method and application thereof. The skin care product comprises, by weight, the following components: 10-15% of folium crataegi composite plant extract, 3-6% of glycerinum, 3-5% of propylene glycol, 3-5% of gamma-polyglutamic acid, 2-5% of trehalose, 0.5-1.0% of triethanolamine, 0.2-0.8% of d-alpha-tocopherol, 0.05-0.1% of hyaluronic acid, 0.05-0.1% of methylparaben, and the balance deionized water. The processes of compound extract and mixed homogeneity are used during the preparation process. According to the invention, the skin care product mainly comprises natural plant components and Chinese herbal active components, has the effects of freckling, skin whitening and free radical scavenging, can change pigmentation from the cell level, and is safe in use. The probability of adverse reaction is extremely low.

The invention discloses walnut-albumin composite powder for nutritional products for pregnant women and a preparation method of the walnut-albumin composite powder. Walnut kernels, albumin powder, glucose powder, oligomerized isomeric maltose, fructo-oligosaccharide, isomaltulose, cyclodextrine, resistant dextrin, d-alpha-tocopherol and vitamin C are adopted as raw materials for preparing excellent dried microcapsule powder by grinding, compounding, homogenizing and spray drying. By adding of a small quantity of mycose, compact vitrified crystal embedding shells are formed for unsaturated fatty acids such as linolenic acid and linoleic acid, and accordingly nutrient stability of the walnut-albumin composite powder is kept to the greatest extent, and the walnut-albumin composite powder, rich in unsaturated fatty acid, suitable for food substances of nutritional products for the pregnant women is finally obtained.

The invention relates to an extraction method of a tocopherol intermediate, belonging to the technical field of organic complexing extraction. The tocopherol intermediate is a product obtained after aminomethylation reaction of non-D-alpha-tocopherol in a tocopherol concentrated solution. The tocopherol concentrated solution contains higher-content mixed tocopherol (D-alpha, beta, gamma and delta-tocopherol), also contains a great amount of glyceride, fatty acid methyl ester, sterol ester and other impurities, and the preparation of high-content D-alpha-tocopherol is hindered by the existence of the impurities. The boiling points of the impurities are close to that of tocopherol, therefore, the impurities cannot be separated from tocopherol by distilling and other methods. The non-D-alpha-tocopherol intermediate is a tertiary amine substance, has certain alkalinity, and can be combined with an acid to form a salt, and glyceride and other impurities are easy to dissolve in an organic solvent. According to the invention, the tocopherol intermediate is extracted from glyceride and other impurities by a liquid-liquid extraction method, and the obtained non-D-alpha-tocopherol intermediate is almost pure, thus the purpose of purification is achieved.

The invention discloses a preparation method of d-alpha-tocopherol polyethylene glycol succinate. The preparation method comprises the following steps: by taking Merrifield resin and PEG1,000 as raw materials and alkali as a catalyst, performing reaction at 45-135 DEG C in an organic solvent to obtain resin loaded with PEG1,000; under the action of the catalyst, enabling the resin loaded with PEG1,000 and d-alpha-tocopherol succinate to be subjected to water diversion reflux reaction to obtain resin loaded with TPGS; and soaking the resin loaded with TPGS in toluene, then adding ethanol, palladium on carbon and phosphopyridoxal, and performing stirring reaction at 100-110 DEG C for 24 hours in hydrogen gas of 0.8-1.5MPa to obtain the d-alpha-tocopherol polyethylene glycol succinate. By adopting the synthetic method disclosed by the invention, the yield of TPGS is as high as 99%, the monoester content of TPGS is 99%, and the diester content of TPGS is 0.

The invention discloses a method for recovery of d-alpha-tocopherol from natural vitamin E leftover material. The high content d-alpha-tocopherol can be prepared from the natural vitamin E extraction leftover material as a raw material by the technology of a combination of rectification and ion exchange chromatography. Specific steps are as follows: the natural vitamin E extraction leftover material is separated by a two-stage rectifying column, a heavy component after two-stage rectifying is used as a raw material for separation by use of ion exchange chromatography, and after adsorption, replacement, desorption, regeneration and other steps, finally the purely natural high content alpha-tocopherol can be prepared by molecular distillation, wherein the content of total tocopherol in the purely natural high content alpha-tocopherol is greater than or equal to 95.0%, and the relative content of the d-alpha-tocopherol in the pure natural high content alpha-tocopherol is greater than or equal to 96.0%. Compared with the d-alpha-tocopherol produced by a traditional preparation method, the d-alpha-tocopherol prepared by the method is not chemically transformed, the method is safer, green, healthy, simple in process, high in separation efficiency, and easy in industrial production, the obtained d-alpha-tocopherol is high in content and low in cost, and the comprehensive utilization of effective components in the leftover material can be realized.